Literature DB >> 25572016

205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands.

Jan L De Bleecker1, Boel De Paepe8, Eleonora Aronica6, Marianne de Visser6, Anthony Amato5, Eleonora Aronica6, Olivier Benveniste7, Jan De Bleecker8, Onno de Boer6, Boel De Paepe8, Marianne de Visser6, Mazen Dimachkie9, Romain Gherardi10, Hans Hilmar Goebel11, David Hilton-Jones12, Janice Holton13, Ingrid E Lundberg14, Andrew Mammen15, Frank Mastaglia16, Ichizo Nishino17, Elisabeth Rushing18, Henrik Daa Schroder19, Duygu Selcen20, Werner Stenzel21.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25572016     DOI： 10.1016/j.nmd.2014.12.001

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  32 in total

1.  Activation of osmolyte pathways in inflammatory myopathy and Duchenne muscular dystrophy points to osmoregulation as a contributing pathogenic mechanism.

Authors:  Boel De Paepe; Jean-Jacques Martin; Sandrine Herbelet; Cecilia Jimenez-Mallebrera; Estibaliz Iglesias; Cristina Jou; Joachim Weis; Jan L De Bleecker
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

2.  Skeletal Muscle Involvement in Antisynthetase Syndrome.

Authors:  Eri Noguchi; Akinori Uruha; Shigeaki Suzuki; Kohei Hamanaka; Yuko Ohnuki; Jun Tsugawa; Yurika Watanabe; Jin Nakahara; Takashi Shiina; Norihiro Suzuki; Ichizo Nishino
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

Review 3.  Idiopathic inflammatory myopathies.

Authors:  Ingrid E Lundberg; Manabu Fujimoto; Jiri Vencovsky; Rohit Aggarwal; Marie Holmqvist; Lisa Christopher-Stine; Andrew L Mammen; Frederick W Miller
Journal:  Nat Rev Dis Primers       Date:  2021-12-02       Impact factor: 52.329

4.  [Long-term rituximab treatment of refractory idiopathic inflammatory myopathy: A report of 3 cases].

Authors:  W X Yi; C J Wei; Y Wu; X H Bao; H Xiong; X Z Chang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

Review 5.  Antisynthetase syndrome: A distinct disease spectrum.

Authors:  Kun Huang; Rohit Aggarwal
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

Review 6.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

7.  Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study.

Authors:  Cécile Picard; Thierry Vincent; Jean-Christophe Lega; Sophie Hue; Françoise Fortenfant; Daniela Lakomy; René-Louis Humbel; Joelle Goetz; Nicolas Molinari; Nathalie Bardin; Daniel Bertin; Catherine Johanet; Pascale Chretien; Sylvain Dubucquoi; Nathalie Streichenberger; Sophie Desplat-Jégo; Xavier Bossuyt; Jean Sibilia; Isabelle Abreu; Alain Chevailler; Nicole Fabien
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

Review 8.  Updates on the Immunopathology in Idiopathic Inflammatory Myopathies.

Authors:  Akinori Uruha; Hans-Hilmar Goebel; Werner Stenzel
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

9.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Authors:  Olivier Benveniste; Lisa G Rider
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

10.  The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China.

Authors:  Xue Ma; Li Xu; Suqiong Ji; Yue Li; Bitao Bu
Journal:  Front Neurol       Date:  2021-07-05       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.